Novel arylsulfoanilide-oxindole hybrid as an anticancer agent that inhibits translation initiation

Amarnath Natarajan, Yuhong Guo, Frederick Harbinski, Yun Hua Fan, Han Chen, Lia Luus, Jana Diercks, Huseyin Aktas, Michael Chorev, Jose A. Halperin

Research output: Contribution to journalArticle

122 Scopus citations

Abstract

Structure-activity relationship studies of substituted arylsulfoanilides as antiproliferatives, which are mediated by the partial depletion of intracellular Ca2+ stores, resulted in the identification of compounds with micromolar activity against lung cancer cells in a growth inhibition assay. Incorporating the substitution pattern of the best arylsulfoanilides onto the 3-phenyloxindole scaffold resulted in a potent arylsulfoanilide-oxindole hybrid, 27. Compound 27 inhibits cancer cell growth by partial depletion of intracellular Ca2+ stores and phosphorylation of eIF2α.

Original languageEnglish (US)
Pages (from-to)4979-4982
Number of pages4
JournalJournal of Medicinal Chemistry
Volume47
Issue number21
DOIs
StatePublished - Oct 7 2004

    Fingerprint

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Natarajan, A., Guo, Y., Harbinski, F., Fan, Y. H., Chen, H., Luus, L., Diercks, J., Aktas, H., Chorev, M., & Halperin, J. A. (2004). Novel arylsulfoanilide-oxindole hybrid as an anticancer agent that inhibits translation initiation. Journal of Medicinal Chemistry, 47(21), 4979-4982. https://doi.org/10.1021/jm0496234